BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 7585591)

  • 1. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121.
    Asano M; Yukita A; Matsumoto T; Kondo S; Suzuki H
    Cancer Res; 1995 Nov; 55(22):5296-301. PubMed ID: 7585591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo.
    Asano M; Yukita A; Matsumoto T; Hanatani M; Suzuki H
    Hybridoma; 1998 Apr; 17(2):185-90. PubMed ID: 9627059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
    Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
    Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody.
    Kondo S; Asano M; Suzuki H
    Biochem Biophys Res Commun; 1993 Aug; 194(3):1234-41. PubMed ID: 7688963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolation and characterization of neutralizing monoclonal antibodies to human vascular endothelial growth factor/vascular permeability factor121 (VEGF/VPF121).
    Asano M; Yukita A; Matsumoto T; Matsuo K; Kondo S; Suzuki H
    Hybridoma; 1995 Oct; 14(5):475-80. PubMed ID: 8575796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
    Prewett M; Huber J; Li Y; Santiago A; O'Connor W; King K; Overholser J; Hooper A; Pytowski B; Witte L; Bohlen P; Hicklin DJ
    Cancer Res; 1999 Oct; 59(20):5209-18. PubMed ID: 10537299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
    Wood JM
    Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralizing anti-vascular endothelial growth factor antibody inhibits further growth of established prostate cancer and metastases in a pre-clinical model.
    Melnyk O; Zimmerman M; Kim KJ; Shuman M
    J Urol; 1999 Mar; 161(3):960-3. PubMed ID: 10022734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.
    Gorski DH; Beckett MA; Jaskowiak NT; Calvin DP; Mauceri HJ; Salloum RM; Seetharam S; Koons A; Hari DM; Kufe DW; Weichselbaum RR
    Cancer Res; 1999 Jul; 59(14):3374-8. PubMed ID: 10416597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells.
    Ciardiello F; Bianco R; Damiano V; Fontanini G; Caputo R; Pomatico G; De Placido S; Bianco AR; Mendelsohn J; Tortora G
    Clin Cancer Res; 2000 Sep; 6(9):3739-47. PubMed ID: 10999768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis.
    Claffey KP; Brown LF; del Aguila LF; Tognazzi K; Yeo KT; Manseau EJ; Dvorak HF
    Cancer Res; 1996 Jan; 56(1):172-81. PubMed ID: 8548760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
    Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
    Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors.
    Zielke A; Middeke M; Hoffmann S; Colombo-Benkmann M; Barth P; Hassan I; Wunderlich A; Hofbauer LC; Duh QY
    Surgery; 2002 Dec; 132(6):1056-63; discussion 1063. PubMed ID: 12490855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential inhibition of fluid accumulation and tumor growth in two mouse ascites tumors by an antivascular endothelial growth factor/permeability factor neutralizing antibody.
    Luo JC; Toyoda M; Shibuya M
    Cancer Res; 1998 Jun; 58(12):2594-600. PubMed ID: 9635584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
    Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
    Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor.
    Hori A; Sasada R; Matsutani E; Naito K; Sakura Y; Fujita T; Kozai Y
    Cancer Res; 1991 Nov; 51(22):6180-4. PubMed ID: 1718597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of antibody against vascular endothelial growth factor on tumor growth].
    Wang G; Wang N; Liu T
    Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):163-6. PubMed ID: 10920886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ.
    Takayama K; Ueno H; Nakanishi Y; Sakamoto T; Inoue K; Shimizu K; Oohashi H; Hara N
    Cancer Res; 2000 Apr; 60(8):2169-77. PubMed ID: 10786681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.